VEGF levels increased after TACE, and the antiangiogenic effect of Regorafenib compensated for the lack, prolonged the duration of chemoembolization, and inhibited tumor recurrence and metastasis; meanwhile, Regorafenib could inhibit tumor cell proliferation through a variety of pathways. This evidence concerns the gene VEGFA and neoplasm.